Helen Mackay

6PUBLICATIONS
24CO-AUTHORS
Predictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 14, 2026
Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012.

|Oct 31, 2024
Advances in Vulvar Cancer Biology and Management.

Rania Chehade, Katarzyna J Jerzak, Farideh Tavanger

|Oct 03, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.

Jung-Min Lee, Mark F Brady, Austin Miller

|Dec 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.

Bobbie J Rimel, Danielle Enserro, David P Bender

Pageof 1

Frequent Collaborators

2 joint publications

Floor J Backes

1 joint publications

Andrew B Nixon

1 joint publications

Bobbie J Rimel

1 joint publications

Italo Fernandes